Indivior Pharmaceuticals IncINDV
ASignal's systematic analysis rates INDV as Neutral.
Reflects the latest available analysis · analyzed Aug 29, 2026
The case on INDV
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin (85.72%) indicating pricing power
- High revenue growth (13.6%)
- Exceptional year-over-year earnings growth (600%)
- Attractive forward P/E of 7.14x
- Free cash flow positive at $86.5M
- Operating margin strong at 46.94%
- Negative MACD histogram suggesting bearish momentum
- Price below both SMA20 and SMA50 indicating downtrend
- Negative operating cash flow (-$40M)
- Low current and quick ratios (0.83x, 0.59x) signaling liquidity concerns
- Negative price-to-book ratio (-19.78x) due to negative book value
- No Reddit mentions, suggesting lack of retail interest or visibility
See the full verdict on INDV
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes INDV
Most investors never get a second opinion, let alone several. ASignal runs INDV past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.